New Delhi: Drugs Controller General of India (DCGI) on Monday approved Biological E’s Covid-19 vaccine Corbevax for emergency use among children aged 12-18 years.
The Hyderabad-based pharmaceutical company’s vaccine had earlier received emergency use authorization from DCGI’s Subject Expert Committee for the 12-18 age group, subject to conditions.
Corbevax, to be administered in two doses, is the third vaccine to be approved for 12-18-year olds in India, the others being Bharat Biotech’s Covaxin and Zydus Cadila’s DNA shot ZyCoV-D.
However, Covaxin is mainly being used currently to inoculate children aged 15-18 years.
Corbevax is expected to cost Rs 145 per dose, excluding taxes, ANI reported quoting sources.
National Technical Advisory Group on Immunisation (NTAGI) chief Dr NK Arora said earlier that Corbevax shots were safe, and offered good immunogenicity and higher antibody levels compared to other vector vaccines.
Mumbai: Television actress Hina Khan, who is battling breast cancer, recently met host Salman Khan…
Mumbai: Following reports of his alleged link-up with bassist Mohini Dey, renowned music composer AR…
Mumbai: The love story of actors Tamannaah Bhatia and Vijay Varma has not been clandestine.…
Puri: Shree Jagannath Temple Administration (SJTA) has received the report of the Ratna Bhandar’s GPR-GPS…
With his debut novel ‘The Other Side of the Rainbow’ published recently, Niranjan Nayak, an…
Bhubaneswar: Odisha outplayed Chhattisgarh 4-1 on Saturday to seal a berth in the final round…
Mumbai: The Telangana government’s notice barring him from singing songs promoting alcohol and drugs at…
Bhubaneswar: Prime Minister Narendra Modi will participate in the ‘Odisha Parba 2024’ programme on Sunday…